Development and validation of a liquid chromatography-tandem mass spectrometry assay for determination of raloxifene and its metabolites in human plasma

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Aug 15;855(2):220-7. doi: 10.1016/j.jchromb.2007.05.004. Epub 2007 May 16.

Abstract

This paper describes the development and validation of a method for the detection of raloxifene (Ral) and its two glucuronide metabolites, raloxifene-6-glucuronide (M1) and raloxifene-4'-glucuronide (M2), in human plasma samples. Both glucuronides were synthesized enzymatically, purified and used as authentic standards. The assay involves a simple solid phase extraction (SPE) procedure of 0.5 mL of human plasma and subsequent analysis by LC-MS-MS. The recoveries were higher than 71% and chromatographic separation of all the analytes was accomplished in less than 7 min. Linear ranges (r(2)>0.99) were found from 0.200 to 340 microg/L, from 1.600 to 2720 microg/L and from 0.088 to 60.00 microg/L, for M1, M2 and Ral, respectively. The limits of detection achieved were 8, 11 and 6 ng/L for M1, M2 and Ral, respectively. The method presented was successfully applied to a genetic polymorphism study of 47 plasma samples from women taking Evista (raloxifene hydrochloride).

Publication types

  • Validation Study

MeSH terms

  • Chromatography, High Pressure Liquid / methods*
  • Female
  • Glucuronosyltransferase / metabolism
  • Humans
  • Raloxifene Hydrochloride / blood*
  • Raloxifene Hydrochloride / isolation & purification
  • Raloxifene Hydrochloride / metabolism
  • Reproducibility of Results
  • Selective Estrogen Receptor Modulators / blood*
  • Selective Estrogen Receptor Modulators / isolation & purification
  • Selective Estrogen Receptor Modulators / metabolism
  • Tandem Mass Spectrometry / methods*

Substances

  • Selective Estrogen Receptor Modulators
  • Raloxifene Hydrochloride
  • Glucuronosyltransferase